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is the formation of venous ulcerations. Several mechanisms
have been proposed to explain the pathogenesis of venous
ulcers. The hypoxic environment resulting from pericapil-
lary fibrin cuff formation,3 leukocyte trapping and activa-
tion with cytokine imbalances,4 endothelial cell activation
and leukocyte diapedisis,5 and growth factor trapping by
macromolecules may all play important roles, either inde-
pendently or in conjunction, during venous ulcer forma-
tion.6 However, no unifying theory for venous ulcer
formation can fully explain this complex disease state.
Recent studies have suggested that fibroblasts cultured
from both patients with chronic venous ulcerations and
patients with CVI without ulcers had reduced growth
capacity and displayed characteristics of cellular senes-
cence.7-9 The hypothesis that cellular senescence may have
a possible etiologic role in the changes observed in the pri-
mary cells responsible for wound healing from patients
with CVI is important in the pathogenesis and therapeu-
tics. Cells that become senescent have the hallmark of irre-
versible arrest of cell proliferation. Once a cell has become
The underlying pathologic condition leading to
chronic venous insufficiency (CVI) is a consequence of
venous hypertension from valve incompetence, obstruc-
tive disease, or both.1 Varicose veins, by definition, have
incompetent valves with increased venous pressure, lead-
ing to progressive dilation and tortuosity. The formation
of these primary varicose veins is multifactorial, with the
main influences related to heredity, female sex hormones,
hydrostatic force, and hydrodynamic muscular compart-
ments.2 The significance of unabated venous hypertension
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Purpose: Fibroblasts (fb) play an important role in wound healing involving motility, contraction, fibrosis, and expres-
sion of the cytoskeletal protein α-smooth muscle actin (α-sma). Patients with chronic venous insufficiency (CVI) are
known to have dermal changes and impaired venous ulcer healing. To investigate whether these dermal-fb have an
altered ability to migrate and whether chronic wound fluid from venous ulcers alters neonatal fb motility, we examined
cell migration and α-sma.
Methods: Fibroblasts were cultured from the margin of venous ulcers (du-fb, n = 4, CEAP 6), from patients with venous
reflux without ulcer (dr-fb, n = 5, CEAP 2), and from the ipsilateral thigh of the same patients with (pu-fb) and with-
out (pr-fb) ulcer, respectively. The abbreviations used are p and d, which represent proximal and distal, respectively; u
and r represent ulcer and reflux, respectively. Neonatal foreskin fibroblasts (nf-fb) were exposed to chronic venous ulcer
wound fluid (CVUWF, 300 µg protein/mL, n = 3) or bovine serum albumin (BSA, control). Fibroblast motility was
determined by means of time-lapse photo-images, and the rate (micrometer per hour) was calculated. Immuno-
histochemistry for α-sma was analyzed with confocal laser microscopy.
Results: The rate of motility (micrometer per hour ± SEM) was decreased for both du-fb (11.4 ± 0.7) and dr-fb (13.8
± 0.6), when compared with pu-fb (21.9 ± 0.9) and pr-fb (24.7 ± 1.1), respectively. The motility rate for nf-fb was
lower in CVUWF (24.7 ± 2.0) than in BSA (37.1 ± 6.7). An elevated level of microfilament bundles of α-sma for both
du-fb and dr-fb, compared with those of pu-fb and pr-fb, and also in nf-fb treated with CVUWF was demonstrated by
means of immunohistochemistry.
Conclusion: These data demonstrate a reduced motility in the dermal fb of patients with CVI. Patients with reflux dis-
ease without ulcer are predisposed to these changes. Furthermore, it appears that CVUWF causes changes in motility
and α-sma expression in nf-fb as demonstrated in du-fb. These findings suggest that reduced motility and CVUWF,
representing the microenvironment of venous ulcers, play a significant role in impaired wound healing. (J Vasc Surg
2001;33:1233-41.)
senescent, it cannot be induced by any combination of
physiologic mitogens to reinitiate DNA synthesis and cell
division.10,11
Wound healing involves a complex series of events that
require inflammation, cellular chemotaxis, neovasculariza-
tion, cytokine and growth factor release, collagen synthe-
sis, and remodeling.12 Fibroblasts are essential in both
normal and disease states of tissue repair. The migration of
fibroblasts within a wound leads to the release of extracel-
lular proteins and mitogens affecting keratinocytes,
endothelial cells, and other fibroblasts. Once a fibroblast
has reached the wound site, it changes into a more con-
tractile and collagen-producing phenotype.13 Several stud-
ies have demonstrated that chronic wounds from venous
ulcers have altered molecular environments for growth
factors, proteins, and cytokines affecting wound heal-
ing.14,15 Furthermore, chronic wound fluid collected from
venous ulcers has been shown to inhibit the growth of
fibroblasts in vitro, possibly explaining the persistence of
the venous ulcer wound and their impaired healing.16-18
Chronic venous hypertension can lead to the forma-
tion of dermal skin changes referred to as lipoder-
matosclerosis, resulting in dermal and subcutaneous tissue
fibrosis and eventual ulceration.3 At the molecular level, it
has been demonstrated that transforming growth factor-
beta 1 released by monocytes plays an important role in
activating fibroblasts, resulting in tissue fibrosis in patients
with CVI.5 Beside venous disease, tissue fibrosis is associ-
ated with several other pathologic states, including liver
cirrhosis, pulmonary fibrosis, and organ transplant rejec-
tion.19,20 Within these diseased tissues there is the persis-
tence of myofibroblasts characterized by the expression of
alpha smooth muscle actin (α-sma). Myofibroblasts are
differentiated fibroblasts possessing contractile properties
necessary for wound contraction and in the formation of
granulation tissue, scarring, and fibrosis.
Because fibroblasts are an essential cell during wound
healing and these same cells can be involved in tissue
fibrosis, the objective of this study was to examine fibro-
blast motility and the expression of α-sma cultured from
patients with CVI. Furthermore, we examined the role of
chronic wound fluid on neonatal fibroblasts by also mea-
suring changes in motility and α-sma expression.
METHODS 
For details of methods, see the Appendix.
Patients
Patients with chronic venous ulcers (CEAP 6, n = 4)
were interviewed and examined. Evaluation of the
severity of venous disease was determined with the
guidelines prepared by the Executive Committee of 
the American Venous Forum.21 Patients who had con-
comitant arterial disease, diabetes mellitus, human
immunodeficiency virus serology, or active infections or
who were taking immunosuppressive medications were
excluded. All arms of the study involving human biopsy
were approved by the Institutional Review Board. After
getting informed consent from the patients, one 4-mm
punch biopsy specimen was obtained from the border of
the ulcer (du-fb) and from the ipsilateral dermal tissue
of the thigh (pu-fb). Patients with CVI CEAP 2 (n = 5)
were enrolled in the study. Venous reflux was deter-
mined by means of venous duplex ultrasonography and
defined by means of retrograde flow and prolonged
valve closure time. The exclusion criteria were those
mentioned earlier. A 4-mm punch biopsy specimen was
obtained from dermal skin in the medial malleolar
region (dr-fb) and from the ipsilateral dermal tissue of
the thigh (pr-fb). Biopsies of specimens from healthy
volunteers (n = 3) without venous hypertension were
performed. These individuals had normal results on
venous studies by means of duplex ultrasonography. A
4-mm punch biopsy specimen was obtained from nor-
mal dermal skin in the medial malleolar region (dn-fb)
and from the ipsilateral skin of the thigh (pn-fb). The
notation indicates d for distal, p for proximal, u for
ulcer, r for reflux, and n for normal.
Chronic venous ulcer wound fluid collection
Wound fluid was obtained from recruited patients as
described earlier.18 The donors for chronic venous ulcer
wound fluid (CVUWF) were not necessarily the same
donors from whom dermal fibroblasts were obtained.
Fibroblasts tissue culture
Skin biopsy specimens from patients with CVI and
from healthy volunteers were obtained within 2 hours of
the procedures, and they were obtained from neonatal
foreskin fibroblasts (nf-fb) after circumcision (through
Institutional Review Board approval from a newborn nurs-
ery). Neonatal fibroblasts have been shown to have the
highest growth capacity among fibroblasts from patients
in all age groups.18 In looking at a model system, our goal
was to evaluate the effect of CVUWF on rapidly prolifer-
ating cells, because we expected that in a wound these cells
would be responsible for healing. The dermal fibroblast
from proximal (normal fibroblasts, pu-fb or pr-fb) sites
from patients with CVI could have been examined; how-
ever, we were interested in testing the fibroblasts with the
highest replicative potential, and those are neonatal fibro-
blasts. Primary cultures from dermal fibroblasts were pre-
pared from the explant technique as described earlier.7
This is an established technique for obtaining purely fibro-
blasts.22 Furthermore, the cells obtained from tissue cul-
ture have been stained for vimentin, analyzed by means of
immunohistochemistry, and were found to stain positive
(positive vimentin is a marker for fibroblasts, but not
smooth muscle cells; data not shown).23
Fibroblast motility
Ulcer, reflux, and normal fibroblasts. Fibroblasts
from patients with ulcer (du-fb and pu-fb), reflux (dr-fb
and pr-fb), and healthy volunteers (dn-fb and pn-fb) were
plated in separate 35 × 10-mm tissue culture dishes at a
concentration of 1000 to 1500 cells per dish in 2 mL of
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complete media (CM) and incubated overnight at 37°C
and 6% CO2. All fibroblasts used in this study were
between the third to the sixth passage, and for each
patient set, the passage was the same. The motility exper-
iments were performed with a Nikon Diaphot inverted
microscope (Donsanto Corp, Natick, Mass) that recorded
cell migration with a charge-coupled device video camera,
as described earlier.24 For each cell, the migration rate in
micrometers per hour was calculated by determining the
sum of the 30-minute migration distances divided by the
total elapsed time (total distance of fb in µm/4 hours). A
mean number of 10 fibroblasts (range, 6-21 fibroblasts)
were analyzed per motility experiment per patient per site,
because this represented the limit of the video camera
image displayed on the monitor.
Neonatal foreskin fibroblasts. Neonatal fibroblasts
(nf-fb) of the third passage were plated in 35 × 10-mm tis-
sue culture dishes at a concentration of 1000 cells per dish
in 2 mL of CM and incubated overnight at 37°C and 6%
CO2. Fibroblasts were re-fed with 2 mL of CM contain-
ing either CVUWF or bovine serum albumin (BSA, con-
trol) at a protein concentration of 300 µg/mL. The
fibroblasts were re-fed at days 1, 3, and 5. The migration
and rate of motility of nf-fb treated with CVUWF or BSA
were determined.24
Immunohistochemistry
Ulcer, reflux, and normal fibroblasts. Fibroblasts
from patients with ulcer (du-fb and pu-fb) and reflux (dr-
fb and pr-fb) and from healthy volunteers (dn-fb and pn-
fb) were plated (100-200 cells per 500 µL of CM) in
tissue culture Lab-Tek 8-well chamber slides (Nalge
Nunc International, Naperville, Ill). Fibroblasts were
immunostained for α-sma and analyzed with confocal
laser microscopy. All fibroblasts used in this study were
between the third to the sixth passage, and for each
patient set, the passage was the same as that of the
fibroblast motility.
Neonatal foreskin fibroblasts. Neonatal fibroblasts
(nf-fb) of the third passage were plated (100 cells per
500 µL of CM) in tissue culture Lab-Tek 8-well chamber
slides (Nalge Nunc International) and incubated.
Fibroblasts were re-fed with 500 µL of CM containing
either CVUWF or BSA at a protein concentration of 300
µg/mL. The fibroblasts were re-fed at days 1, 3, and 5
before immunostaining. Fibroblasts were immunostained
for α-sma and analyzed with confocal laser microscopy.
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Statistical analysis
Statistical analysis was performed with Sigma Stat soft-
ware licensed to Boston University. Comparison of motil-
ity rates expressed as micrometers per hour ± SEM was
analyzed with the Student t test and the Mann-Whitney
rank sum test. Statistical significance was defined at a P
level of .05 or less.
RESULTS
Patients
Four patients with venous ulcer completed all phases
of the study, and five patients with venous reflux com-
pleted the study. Patients with ulcers (CEAP 6) had a
mean clinical score of 13 (range, 11-14). The mean age of
patients with venous ulcers was 53 years (range, 36-67
years). Patients with venous reflux without ulcer (CEAP
2) had a mean age of 58 years (range, 48-63 years). The
classification system was based on the American Venous
Forum guidelines.21 Three healthy volunteers without
venous hypertension were enrolled; they had a mean age
of 47 years (range, 42-56 years). However, fibroblasts
from only two healthy volunteers were analyzed because
of the cell contamination of one volunteer. Three donors
were recruited for CVUWF collection. The average age of
these donors was 50 years (range, 45-57 years); all donors
had recurrent venous ulcers, and the average duration of
the ulcer was 6 months.
Motility
Fibroblasts from ulcer and reflux. The individual
fibroblast motility was tracked for 33 du-fb and 49 pu-fb
fibroblasts and 63 dr-fb and 49 pr-fb fibroblasts, and the
rate was determined. The migration rate of the fibroblasts
in CM from du-fb and dr-fb were significantly decreased
compared with pu-fb and pr-fb, respectively (Table I).
This was observed for all patients tested. When comparing
ulcer and reflux fibroblasts, the motility rate for du-fb
(11.4 ± 0.7 µm/h) was lower than that of dr-fb (13.8 ±
0.6 µm/h, P = .006), and the motility for pu-fb was sim-
ilar to that for pr-fb (P = .15).
Fibroblasts from healthy volunteers. The individ-
ual fibroblast motility was tracked for 15 dn-fb and 14 pn-
fb fibroblasts. The rate of motility for dn-fb (27.2 ± 1.1
µm/h) and for pn-fb (29.2 ± 1.1 µm/h) was not statisti-
cally different (P = .21).
Fibroblasts from neonates. The individual fibro-
blast motility was tracked for 35 nf-fb fibroblasts treated
Table I. Rate (micrometer per hour ± SEM) of fibroblast motility from patients with ulcer and reflux disease without
ulcer
Ulcer Reflux
pu-fb du-fb pr-fb dr-fb
21.9 ± 0.9 11.4 ± 0.7 24.7 ± 1.1 13.8 ± 0.6
P < .0001 P < .0001
Comparison of motility rates between du-fb and dr-fb was significant (P = .006). No difference in motility was noted between pu-fb and pr-fb (P = .15).
with CVUWF and 10 nf-fb fibroblasts treated with BSA.
CVUWF from 3 different donors was tested for the effect
of nf-fb motility. The CVUWF-treated nf-fb fibroblasts
from all 3 donors demonstrated decreased motility rates
compared with those of nf-fb fibroblasts treated with BSA
(Table II).
Immunohistochemistry
Fibroblasts from ulcer and reflux. Immunohisto-
chemistry for α-sma demonstrated an increased level of
cytoskeletal microfilament bundles in both du-fb and dr-
fb fibroblasts, but not in pu-fb and pr-fb fibroblasts. This
was observed in the fibroblasts of all ulcer and reflux
patients who were examined. A representative (ulcer or
reflux fibroblasts) confocal laser micrograph is shown (Fig
1). We did not quantify α-sma by means of the Western
blot analysis and densitometry to assign a numerical value;
however, this was not necessary because the results were
unequivocal in demonstrating the presence of microfila-
ment bundles α-sma by means of immunohistochemical
analysis in the distal ulcer and reflux fibroblasts (thereby
increased expression) and not in the proximal control
fibroblasts. Furthermore, immunohistochemistry has the
advantage of being a means of examining the presence or
absence of α-sma within the fibroblasts with direct micro-
scopic inspection.
Fibroblasts from healthy volunteers. Immunohis-
tochemistry for the presence of α-sma microfilament bun-
dles in the fibroblasts of both healthy volunteers who were
examined was not demonstrated in either dn-fb or pn-fb
fibroblasts (Fig 2).
Fibroblasts from neonates. Immunohistochemistry
for α-sma demonstrated an increased level of cytoskeletal
microfilament bundle staining of nf-fb fibroblasts treated
with CVUWF, but not in nf-fb fibroblasts treated with BSA.
The CVUWF from all three donors resulted in the expres-
sion of α-sma in nf-nb. A representative confocal micro-
graph is shown (Fig 3).
DISCUSSION
Earlier, we hypothesized and demonstrated that fibro-
blasts cultured from patients with chronic venous disease,
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Fig 1. Immunohistochemistry analysis of α-smooth muscle actin in fibroblasts cultured from patients with chronic venous disease.
Confocal laser micrograph is representative image for either fibroblasts pu-fb or pr-fb (proximal, p-fb) and for either du-fb or dr-fb (dis-
tal, d-fb). Arrows indicate α-smooth muscle actin microfilament bundles, which appear as linear arrays and are expressed in d-fb but not
in p-fb. Speckled fluoroisothiocyanate conjugate seen in p-fb represents background signal.
Table II. Rate (micrometer per hour ± SEM) of neona-
tal fibroblast motility treated with bovine serum albumin
or chronic venous ulcer wound fluid
BSA CVUWF
37.1 ± 6.7 24.7 ± 2.0
P = .02
with and without ulcer, have characteristics of cellular
senescence. The presence of senescent fibroblasts within
the region of the lower extremity may play an important
role in the pathogenesis of chronic venous disease.7-9 In
addition, the presence of CVUWF in the microenviron-
ment of venous ulcers appears to adversely affect healing
of these wounds and induce cellular senescence of dermal
fibroblasts.14,16-18 The objective of this study was to inves-
tigate the migration of fibroblasts in tissue culture and the
associated changes in cytoskeletal actin filaments from
patients with CVI. Furthermore, we investigated the effect
of CVUWF on neonatal fibroblasts and hypothesized that
cell motility and α-sma expression would exhibit changes
reflecting the microenvironment of the fibroblasts of
patients with venous ulcer. Our results indicate that fibro-
blasts from patients with CVI both with and without ulcer
have impaired cellular motility and express α-sma, a
marker for myofibroblast activity.19,25,26 Also, the pres-
ence of CVUWF causes both a reduction of cell motility
and expression of α-sma in neonatal fibroblasts. These lat-
ter findings suggest that CVUWF representing the
microenvironment of venous ulcers may have a significant
role in impairing wound healing.
Fibroblasts are an important cell in wound healing,
involved with functions of migration, production of extra-
cellular protein, mitogens, cytokines, and contraction and
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remodeling of the wound.12,13 The intrinsic complexity of
fibroblast migration within a wound requires actin, actin-
binding proteins, microtubules, and intermediate filaments
both bound and unbound within the cytoskeletal array of
the cell cytoplasm.27-30 These proteins allow the fibroblasts
to undergo widespread coordinated movements of the
entire cell surface over other cells or the extracellular
matrix.31 This study demonstrated an inherent reduction
in the motility of fibroblasts from patients with CVI and
neonatal fibroblasts treated with CVUWF. Fibroblasts
from venous ulcers had a small but significant reduction in
migration rate compared with fibroblasts from patients
with reflux and no ulcer. These findings could be explained
by venous ulcer fibroblasts (CEAP 6) being at a more
advanced stage of cellular senescence than venous reflux
fibroblasts (CEAP 2) and may have clinical implications
regarding the healing of venous ulcers.32 Furthermore,
healthy volunteers without venous hypertension did not
have any significant difference in motility or increases in α-
sma expression between fibroblasts cultured from proximal
and distal lower-extremity regions. Consistent with earlier
studies, this finding would exclude the possibility that the
differences related to motility and α-sma was because of
the site chosen.9 The decrease in motility observed in
fibroblasts from patients with CVI and neonatal fibroblasts
treated with CVUWF may be a characteristic of senescent
Fig 2. Immunohistochemistry analysis of α-smooth muscle actin in fibroblasts cultured from healthy donors without venous hyperten-
sion (pn-fb and dn-fb). There is no expression of α-smooth muscle actin in either pn-fb or dn-fb. Speckled fluoroisothiocyanate conju-
gate seen represents background signal.
cells, particularly in a pathologic condition such as venous
disease. It is known that senescent cells have properties of
decreased proliferation, growth factor attenuation, and
possibly motility alterations.33 This study supports the
hypothesis that fibroblasts with senescent characteristics
have decreased cell motility. We have found no literature
citing other types of disease processes such as ischemic,
pressure, or diabetic foot ulcers and decreased fibroblast
motility in vitro. It appears that altered cell motility is a spe-
cific finding to venous disease, and further studies will need
to address whether other types of chronic wounds exhibit
this property.
The second objective of this study was to define the
expression of the cytoskeletal actin filament α-sma. The
expression of α-sma in fibroblasts from patients with CVI
is not exclusive to this disease process. This cytoskeletal
protein is known to be present in fibroblasts of wounded
tissue, both acute and chronic. However, the persistence
of α-sma expression in myofibroblasts can lead to tissue
fibrosis and altered tissue integrity and function.19 During
the acute phase of wounding, fibroblasts are activated to
myofibroblasts with specific functions of extracellular pro-
tein production (collagen and fibronectin) and exhibiting
contractile properties for mediating wound contraction
during the formation of a normal scar and subsequently
disappear by apoptosis.19,25,26 However, in excessive scar-
ring (eg, hypertrophic scar) and pathologic conditions
(eg, pulmonary fibrosis) myofibroblasts expressing α-sma
persist, leading to tissue fibrosis. The significance and fac-
tors regulating myofibroblasts expressing α-sma is not well
understood. Myofibroblasts develop several ultrastructural
and biochemical features of smooth muscle cells, including
cytoskeletal microfilament bundles and the expression of
α-sma. The structural protein α-sma is 1 of the 6 different
actin isoforms, which is found in contractile vascular
smooth muscle cells. The cytoskeletal protein actin forms
the basis of cellular movements in virtually all eucariotic
cells and forms a complex network with microtubules and
intermediate filaments. These proteins provide the frame-
work for the cell and are intimately associated with the cell
organelles, cytoplasm, and the cell membrane. These
cytoskeletal proteins in turn interact with the cell mem-
brane and cytoplasm through accessory proteins and
actin-binding proteins. It is the accessory and binding
proteins that render cells to have shape, strength, and an
ability to move, and their effects are coordinated through
the interaction of intracellular signaling molecules and
high-energy phosphate groups catalyzed by adenosine
triphosphatase.19,34 Although α-sma is both a structural
and contractile cytoskeletal protein, the changes in migra-
tory rates observed in fibroblasts from patients with CVI
cannot solely be attributed to α-sma, because a defect in
any of the accessory or binding proteins or signaling path-
ways may affect cell motility. Furthermore, the expression
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Fig 3. Immunohistochemistry analysis of α-smooth muscle actin in neonatal foreskin fibroblasts (nf-fb). Confocal laser microscopy
demonstrates α-smooth muscle actin expression in nf-fb treated with chronic venous ulcer wound fluid (CVUWF) but not with bovine
serum albumin (BSA).
of α-sma in fibroblasts during an acute versus a chronic
wound (pathologic condition) may in the latter case lead
to the recruitment of fibroblast subtypes with the modu-
lation of phenotypic features that may have implications
on cell migration.19,35 However, in a recent study, a
migration assay of fibroblast strains with and without α-
sma demonstrated that α-sma was a signal for decreased
fibroblast motility. The effect of α-sma on fibroblast
motility could be reversed by specific monoclonal anti-
bodies to α-sma.36 This study demonstrated that both
ulcer and reflux fibroblasts expressed α-sma. Fibroblasts
from patients with venous reflux disease without ulcer (ie,
no visible wounds) express α-sma. When neonatal fibro-
blasts were treated with CVUWF, this led to the expres-
sion of α-sma. It is apparent that a substance or substances
with the molecular property of either cytokines, proteins,
or an unidentified compound within CVUWF induces
motility and α-sma changes in highly proliferative fibro-
blasts and may explain the impaired wound healing in
venous ulcers.14-18 Venous hypertension is known to be
present in both CEAP 2 and CEAP 6 patients. We do not
have an answer about why the reduced motility and
increased expression of α-sma is similar for fibroblasts 
cultured from patients with venous hypertension with
(CEAP 6) and without (CEAP 2) ulcer. The compo-
nent(s) could be a secreted product from a cell or differ-
ent cells within the malleolar dermal tissue and in the ulcer
environment, or it may be an intrinsic property of
CVUWF. Once the substance(s) in CVUWF has been
determined, we could examine fibroblasts cultured from
patients with CVI and evaluate them for transcriptional
(messenger RNA) and protein products. The conditioned
media and CVUWF should be examined for secreted com-
ponent(s) and treated with neutralizing antibody to assess
fibroblast reversibility on decreased motility and α-sma
expression. Also, a model system inducing exogenous
pressure onto fibroblasts and examining for substance for-
mation could link venous hypertension and the unknown
substance(s). Further studies to delineate the active com-
ponent(s) in CVUWF and determining whether fibro-
blasts or other cell types from patients with CVI are
involved in elaborating the component(s) in CVUWF will
be required.
A number of pathologic conditions, including hepatic
cirrhosis, transplant rejection, pulmonary fibrosis, rheuma-
toid joint disease, and excessive scar formation, have been
associated with the persistence of myofibroblasts expressing
α-sma in these tissues.19,20,37,38 Several studies have
demonstrated that transforming growth factor-β (TGF-β)
induces the formation of myofibroblasts differentia-
tion.19,37,39 The pathogenesis leading to dermal tissue
fibrosis in chronic venous disease is poorly understood, but
appears to be related to the activation of fibroblasts by
TGF-β.5 We could speculate that the persistence of senes-
cent fibroblasts expressing α-sma and stimulated by TGF-β
is perpetuated by the presence of CVUWF, leading to fibro-
sis and impaired healing of venous ulcers. Further studies
will be required to evaluate why patients with venous reflux
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and no visible wounds (CEAP 2) demonstrate a reduction
in motility and α-sma expression and whether various
cytokines, antagonist, and growth factors are able to reverse
the changes associated with migration and α-sma expres-
sion.
CONCLUSION
This study has demonstrated that fibroblasts from
patients with CVI have reduced motility and myofibro-
blastic phenotype. Furthermore, CVUWF has a profound
effect on neonatal fibroblast motility and α-sma expres-
sion. This latter finding is a model system reflecting the
microenvironment of the venous ulcer. The presence of
CVUWF leading to the persistence of myofibroblasts in
the venous ulcer may explain the impaired healing proper-
ties observed clinically. Whether cellular senescence is a
cause or an effect of venous ulcer formation is not known.
Earlier studies have demonstrated that fibroblasts cultured
from patients with CVI have characteristics of cellular
senescence and that fibroblasts treated with CVUWF
develop characteristics of cellular senescence. What is not
known about CVUWF is what component(s) may be
involved and which cell(s), if any, may be involved in its
production. We do not know whether the wound fluid
possesses an intrinsic property or whether a cell type with
senescent characteristics is responsible for producing the
compound(s) and secreting within the venous ulcer
microenvironment. Further studies will be required to
evaluate the role of cytokines, CVUWF, growth factors, α-
sma antagonist, and regulatory proteins in the changes
observed for motility and cytoskeletal actin filaments in
fibroblasts from patients with chronic venous disease.
We thank the National Institute of Health Confocal
Facility at Boston University School of Medicine and
Daniel E. Young, BS, and Nicole Jalebert, BS, for their
assistance with the immunohistochemistry preparations. 
REFERENCES
1. Flanigan DP, Goodreau JJ, Burnham SJ, Bergan JJ, Yao JST. Vascular
laboratory diagnosis of clinically suspected acute deep vein thrombo-
sis. Lancet 1978;2:331-4.
2. Bergan JJ. Surgical management of primary and recurrent varicose
veins. In: Gloviczki P, Yao JST, editors. Handbook of venous disor-
ders: guidelines of the American Venous Forum. 1st ed. New York:
Chapman and Hall; 1996. p. 394-415.
3. Burnand KG, Whimster I, Naidoo A, Browse NL. Pericapillary fibrin
in the ulcer-bearing skin of the leg: the cause of lipodermatosclerosis
and venous ulceration. BMJ 1988;285:1071-2.
4. Scott HJ, Coleridge Smith PD, Scurr JH, Dormandy JA. Histological
study of white blood cells and their association with lipodermatoscle-
rosis and venous ulceration. Br J Surg 1991;78:210-1.
5. Pappas PJ, You R, Rameshwar P, Gorti R, DeFouw DO, Phillips CK,
et al. Dermal tissue fibrosis in patients with chronic venous insuffi-
ciency is associated with increased transforming growth factor-β1 gene
expression and protein production. J Vasc Surg 1999;30:1129-45.
6. Falanga V, Eaglstein WH. The trap hypothesis of venous ulceration.
Lancet 1993;341:1006-8.
7. Stanley AC, Park HY, Phillips TJ, Russakovsky V, Menzoian JO.
Reduced growth of dermal fibroblasts from chronic venous ulcers can
be stimulated with growth factors. J Vasc Surg 1997;26:994-1001.
8. Mendez MV, Stanley A, Park HY, Shon K, Phillips T, Menzoian JO.
Fibroblasts cultured from venous ulcers display cellular characteristics
of senescence. J Vasc Surg 1998;28:876-83.
9. Mendez MV, Stanley A, Phillips T, Murphy M, Menzoian JO, Park
HY. Fibroblasts cultured from distal lower extremities in patients with
venous reflux display cellular characteristics of senescence. J Vasc Surg
1998;28:1040-50.
10. Campisi J. The biology of replicative senescence. Eur J Cancer
1997;33:703-9.
11. Goldstein S. Replicative senescence: the human fibroblast comes of
age. Science 1990;249:1129-33.
12. Schultz GS, Mast BA. Molecular analysis of the environment of heal-
ing and chronic wounds: cytokines, proteases, and growth factors.
Wounds 1998;10 Suppl F:1F-9.
13. Ågren MS, Steenfos HH, Dabelsteen S, Hansen JB, Dabelsteen E.
Proliferation and mitogenic response to PDGF-BB of fibroblasts iso-
lated from chronic venous leg ulcers is ulcer-age dependent. J Invest
Dermatol 1999;112:463-9.
14. Falanga V. Growth factors and chronic wounds: the need to under-
stand the microenvironment. J Dermatol 1992;19:667-72.
15. Kirsner RS, Katz MH, Eaglstein WH, Falanga V. The biology of
wound fluid. Wounds 1993;5:122-8.
16. Bucalo B, Eaglstein WH, Falanga V. Inhibition of cell proliferation by
chronic wound fluid. Wound Repair Regen 1993;1:181-6.
17. Phillips TJ, Al-Amoudi HO, Leverkus M, Park HY. Effect of chronic
wound fluid on fibroblasts. J Wound Care 1998;7:527-32.
18. Mendez MV, Raffetto JD, Phillips TJ, Menzoian JO, Park HY. The
proliferative capacity of neonatal skin fibroblasts is reduced after expo-
sure to venous ulcer fluid: a potential mechanism for senescence in
venous ulcers. J Vasc Surg 1999;30:734-43.
19. Desmoulière A. Factors influencing myofibroblast differentiation dur-
ing wound healing and fibrosis. Cell Biol Int 1995;19:471-6.
20. Pedagogos E, Hewitson TD, Walker RG, Nicholls KM, Becker GJ.
Myofibroblast involvement in chronic transplant rejection. Transplan-
tation 1997;64:1192-7.
21. Bergan JJ, Eklof B, Kistner RL, Moneta GL, Nicolaides AN.
Classification and grading of chronic venous disease in the lower
limbs: a consensus statement. In: Gloviczki P, Yao JST, editors.
Handbook of venous disorders: guidelines of the American Venous
Forum. 1st ed. New York: Chapman and Hall; 1996. p. 652-60.
22. Gilchrest BA, Karassik RL, Wilkins LM, Vrabel MA, Maciag T.
Autocrine and paracrine growth stimulation of cells derived from
human skin. J Cell Physiol 1983;117:235-40.
23. Alberts B, Bray D, Lewis J, Roff M, Roberts K, Watson JD. The
cytoskeleton. In: Alberts B, Bray D, Lewis J, Roff M, Roberts K,
Watson JD, editors. Molecular biology of the cell. 3rd ed. New York:
Garland Publishing; 1994. p. 787-862.
24. Byers HR, Etoh T, Doherty JR, Sober AJ, Mihm MCJ. Cell migration
and actin organization in cultured human primary, recurrent cuta-
neous and metastatic melanoma. Am J Pathol 1991;139:423-35.
25. Kirk TZ, Mark ME, Chua CC, Chua BH, Mayes MD. Myofibroblasts
from scleroderma skin synthesize elevated levels of collagen and tissue
inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1.
J Biol Chem 1995;270:3423-8.
26. O’Brien JEJ, Shi Y, Fard A, Bauer T, Zalewski A, Mannion JD.
Wound healing around and within saphenous vein bypass grafts. J
Thorac Cardiovasc Surg 1997;114:38-45.
27. Byers HR, White GE, Fujiwara K. Organization and function of stress
fibers in cells in vitro and in situ: a review. Cell Muscle Motil
1984;5:83-137.
28. Amberg DC. Three-dimensional imaging of the yeast actin cytoskele-
ton through the budding cell cycle. Mol Biol Cell 1998;9:3259-62.
29. Waterman-Storer CM. Microtubules and microscopes: how the devel-
opment of light microscopic imaging technologies has contributed to
discoveries about microtubule dynamics in living cells. Mol Biol Cell
1998;9:3263-71.
30. Guillen N, Carlier MF, Brugerolle G, Tardieux I, Ausseil J.
Cytoskeletal actin and its associated proteins. Some examples in pro-
tista. Parasite 1998;5:107-17.
31. Bray D. Migration of cells over surface. In: Bray D, editor. Cell move-
ments. 1st ed. New York: Garland Publishing; 1992. p. 17-29.
32. Raffetto JD, Mendez MV, Phillips TJ, Park HY, Menzoian JO. The
effect of passage number on fibroblast cellular senescence in patients
with chronic venous insufficiency with and without ulcer. Am J Surg
1999;178:107-12.
33. Goldstein S. Replicative senescence: the human fibroblast comes of
age. Science 1990;249:1129-33.
34. Bray D. Actin filaments: structure and assembly. In: Bray D, editor. Cell
movements. 1st ed. New York: Garland Publishing; 1992. p. 75-92.
35. Komuro T. Re-evaluation of fibroblasts and fibroblast-like cells. Anat
Embryol 1990;182:103-12.
36. Ronnov-Jessen L, Petersen OW. A function for filamentous alpha-
smooth muscle actin: retardation of motility in fibroblasts. J Cell Biol
1996;134:67-80.
37. Mattey DL, Dawes PT, Nixon NB, Slater H. Transforming growth
factor β1 and interleukin 4 induce α smooth muscle actin expression
and myofibroblast-like differentiation in human synovial fibroblasts in
vitro: modulation by basic fibroblast growth factor. Ann Rheum Dis
1997;56:426-31.
38. Cass DL, Sylvester KG, Yang EY, Crombleholme TM, Adzick NS.
Myofibroblast persistence in fetal sheep wounds is associated with scar
formation. J Pediatr Surg 1997;32:1017-21.
39. Shi Y, O’Brien JEJ, Fard A, Zalewski A. Transforming growth fac-
tor–beta 1 expression and myofibroblast formation during arterial
repair. Arterioscler Thromb Vasc Biol 1996;16:1298-1309.
Submitted Feb 16, 2000; accepted Oct 16, 2000.
APPENDIX
Chronic venous ulcer wound fluid collection.
Wound fluid was obtained from recruited patients as
described earlier.18 In brief, a foam wafer dressing (Allevyn)
was placed directly over the ulcer and covered by a com-
pressive bandage (Unna’s boot). The chronic venous ulcer
wound fluid (CVUWF) was collected weekly by extracting
it from the Allevyn with a sterile syringe and 20-gauge nee-
dle, and it was diluted 1-to-10 with Dulbecco modified
Eagle medium (DMEM, GibcoBRL Life Technologies,
Gaithersburg, Md). After the addition of aprotinin (2
µg/mL) and phenylmethylsulfonyl fluoride (10 µg/mL),
the diluted CVUWF was filtered through a 0.2-µm tissue
culture filter to remove debris and bacteria. The CVUWF
was placed in 1-mL vials and kept frozen at –70°C until fur-
ther use. The donors for CVUWF were not necessarily the
same donors from whom dermal fibroblasts were obtained.
Fibroblast tissue culture. Primary cultures from der-
mal fibroblasts were prepared from the explant technique
as described earlier, with minor modifications.7 In brief,
the subcutaneous fat from the biopsy specimen was dis-
sected away with scissors, followed by a 1-minute povi-
done-iodine bath, 1-minute 70% ethanol bath, and
1-minute phosphate-buffered saline (PBS) bath. The epi-
dermis was separated from the dermis after overnight
incubation with 0.25% trypsin (GibcoBRL Life
Technologies) at 4°C. The dermal tissue was isolated
under sterile conditions, cut into 1- to 2-mm sections, and
placed in 60 × 15-mm etched tissue culture dishes (Becton
Dickinson, Franklin Lakes, NJ). Primary fibroblasts were
then cultured on tissue culture dishes in DMEM contain-
ing 10% calf serum (complete media [CM]). Cells were
then expanded from the explant. Two groups of fibro-
blasts were obtained from each patient with chronic
venous insufficiency with ulcer CEAP 6 (pu-fb and du-fb)
and without ulcer CEAP 2 (pr-fb and dr-fb) and from
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healthy volunteers (pn-fb and dn-fb), and 1 group of
neonatal foreskin fibroblasts (nf-fb) was obtained.
Fibroblasts were passed into separate sets of tissue culture
dishes (passage 1). Cells were kept in a humidified incu-
bator with constant 6% CO2 at 37°C. Cells were then
expanded and stored (1 × 106 cells/vial) at –140°C in liq-
uid nitrogen. A vial of cryopreserved cells was thawed and
replated in CM for each experiment and incubated as
aforementioned.
Fibroblast motility. The motility experiments were
performed as described earlier.24 In brief, within 24 hours
of plating, the tissue culture dish was placed over a Nikon
Diaphot inverted microscope with a 10× phase contrast
objective with an attached sealed Plexiglas incubator hous-
ing, Nikon incubator (NP-2) with stage thermostat
(Donsanto, Natick, Mass) and Sheldon lab 2004 CO2
mixer (Cornelius, Ore) to obtain constant temperature
and pH (37°C, 5% CO2 and 95% air). The cells’ migration
was recorded with a charge-coupled device video camera
attached to a video camera port and connected to a com-
puter-operated time-lapse frame grabber (Signal Analytics,
Vienna, Va). The fibroblast motility was recorded for 4
hours, and the interval between frames was 30 minutes.
The grabbed images at the various intervals were analyzed
with the Explorer image analysis system from IPLab
Spectrum version 2.5.5 (Signal Analytics) with a video
frame grabber interfaced on a PowerMac computer (Apple
Computer, Cupertino, Calif).
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Immunohistochemistry. Fibroblasts were plated
(100-200 cells per 500 µL of CM) in tissue culture Lab-
Tek 8-well chamber slides (Nalge Nunc International) and
then incubated at 37°C and 6% CO2 for 24 to 48 hours.
After incubation, the fibroblasts in each well were washed
in 1× PBS three times, and 100 µL of fixative (5% forma-
lin containing 2 mmol/L each of EGTA [pH 7.5 to 8.0]
and MgCl) was added for 15 minutes at room temperature
(RT). Cells were then washed with 1× PBS three times.
Next, fibroblasts were treated with 100 µL of Triton-X 100
in PBS for 2 minutes at RT. Cells were then washed with
1× PBS three times. To each well 100 µL of 5% goat serum
in PBS was added and incubated at 37°C for 30 minutes.
Cells were then washed with 1× PBS three times. The pri-
mary antibody monoclonal anti-α smooth muscle actin
(Sigma, St Louis, Mo) was prepared (1:400, diluted in PBS
and 0.5% BSA stored on ice), and 100 µL was added to
each well and incubated at 37°C for 1 hour. Cells were
then washed with 1× PBS three times. The secondary anti-
body goat antimouse IgG fluoroisothiocyanate conjugate
(Sigma) was prepared (1:80, diluted in PBS and 0.5% BSA
stored on ice), and 100 µL was added to each well and
incubated at 37°C for 1 hour. Cells were then washed with
1× PBS three times, followed by one to two drops of
Slofade, and cover slip sealed with nail polish. The fibro-
blasts were analyzed by using confocal laser scanning
microscopy Zeiss model LSM510 axiovert 100 mol/L
with a 25× power objective (Carl Zeiss, Thornwood, NY).
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